Trial Profile
A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of EQ001 in Subjects With Newly Diagnosed Acute Graft Versus Host Disease
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Mar 2023
Price :
$35
*
At a glance
- Drugs Itolizumab (Primary) ; Corticosteroids
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms EQUATE
- Sponsors Equillium
- 07 Mar 2023 Status changed from recruiting to completed.
- 17 Feb 2023 According to an Equillium media release, the oral presentation at the Tandem Meetings of ASTCT and CIBMTRis available on the Presentations page of Equilliums website.
- 17 Feb 2023 According to an Equillium media release, results from this study presented as oral Presentation at the Tandem Meetings of ASTCT and CIBMTR